Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution

Danoprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that promotes multi-log(10) reductions in HCV RNA when administered as a 14-day monotherapy to patients with genotype 1 chronic HCV. Of these patients, 14/37 experienced a continuous decline in HCV RNA, 13/37 a plateau, and 10/37 a re...

詳細記述

保存先:
書誌詳細
主要な著者: Lim, Sharlene R., Qin, Xiaoli, Susser, Simone, Nicholas, John B., Lange, Christian, Herrmann, Eva, Hong, Jin, Arfsten, Ann, Hooi, Lisa, Bradford, Williamson, Nájera, Isabel, Smith, Patrick, Zeuzem, Stefan, Kossen, Karl, Sarrazin, Christophe, Seiwert, Scott D.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology 2012
主題:
Antiviral Agents
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3256012/
https://ncbi.nlm.nih.gov/pubmed/22064535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05636-11
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料